Research ExplorerPublicationsTemporal changes and regional differences in treatment uptak...

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

Standard

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. / Grint, D; Peters, L; Schwarze-Zander, C; Beniowski, M; Pradier, C; Battegay, M; Jevtovic, D; Soriano, V; Lundgren, J D; Rockstroh, J K; Kirk, O; Mocroft, A; EuroSIDA in EuroCoord.

In: HIV MED, Vol. 14, No. 10, 01.11.2013, p. 614-23.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grint, D, Peters, L, Schwarze-Zander, C, Beniowski, M, Pradier, C, Battegay, M, Jevtovic, D, Soriano, V, Lundgren, JD, Rockstroh, JK, Kirk, O, Mocroft, A & EuroSIDA in EuroCoord 2013, 'Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA', HIV MED, vol. 14, no. 10, pp. 614-23. https://doi.org/10.1111/hiv.12068

APA

Grint, D., Peters, L., Schwarze-Zander, C., Beniowski, M., Pradier, C., Battegay, M., Jevtovic, D., Soriano, V., Lundgren, J. D., Rockstroh, J. K., Kirk, O., Mocroft, A., & EuroSIDA in EuroCoord (2013). Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV MED, 14(10), 614-23. https://doi.org/10.1111/hiv.12068

Vancouver

Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M et al. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV MED. 2013 Nov 1;14(10):614-23. https://doi.org/10.1111/hiv.12068

Bibtex

@article{53a1a50c3b3d4c83a4e3b97c26beb6f4,
title = "Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA",
abstract = "OBJECTIVES: All HIV/hepatitis C virus (HCV)-coinfected patients with chronic HCV infection and ≥ F2 fibrosis should be considered for HCV therapy. This study aimed to determine the rate of HCV treatment uptake among coinfected patients in Europe.METHODS: EuroSIDA patients with viraemic HCV infection were included in the study. Poisson regression was used to identify temporal changes and regional differences in HCV treatment uptake.RESULTS: A total of 1984 patients were included in the study, with a median follow-up time of 168 months [interquartile range (IQR) 121-204 months]. To date, 501 (25.3%) HIV/HCV-coinfected patients have received HCV therapy. Treatment incidence rose from 0.33 [95% confidence interval (CI) 0.16-0.50] per 100 person-years of follow-up (PYFU) in 1998 to 5.93 (95% CI 4.49-7.38) in 2007, falling to 3.78 (95% CI 2.50-5.07) in 2009. After adjustment, CD4 cell count > 350 cells/μL [incidence rate ratio (IRR) 1.33 (95% CI 1.06-1.67) vs. CD4 count 200-350 cells/μL] and ≥F2 liver fibrosis [IRR 1.60 (95% CI 1.14-2.25; P = 0.0065) vs. < F2 fibrosis] were predictors of anti-HCV treatment initiation. However, 22% of patients who remain untreated for HCV, with fibrosis data available, had ≥F2 fibrosis and should have been considered for treatment, while only 36% of treated patients had ≥F2 fibrosis.CONCLUSIONS: Although treatment incidence for HCV has increased, there remain a large proportion of patients indicated for treatment who have yet to be treated.",
keywords = "Adult, Antiviral Agents, CD4 Lymphocyte Count, Cohort Studies, Coinfection, Drug Therapy, Combination, Europe, Female, HIV Infections, Hepatitis C, Chronic, Humans, Interferon-alpha, Liver Cirrhosis, Male, Middle Aged, Patient Acceptance of Health Care, Poisson Distribution, Prospective Studies, Ribavirin",
author = "D Grint and L Peters and C Schwarze-Zander and M Beniowski and C Pradier and M Battegay and D Jevtovic and V Soriano and Lundgren, {J D} and Rockstroh, {J K} and O Kirk and A Mocroft and {EuroSIDA in EuroCoord} and {van Lunzen}, Jan",
note = "{\textcopyright} 2013 British HIV Association.",
year = "2013",
month = nov,
day = "1",
doi = "10.1111/hiv.12068",
language = "English",
volume = "14",
pages = "614--23",
journal = "HIV MED",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

AU - Grint, D

AU - Peters, L

AU - Schwarze-Zander, C

AU - Beniowski, M

AU - Pradier, C

AU - Battegay, M

AU - Jevtovic, D

AU - Soriano, V

AU - Lundgren, J D

AU - Rockstroh, J K

AU - Kirk, O

AU - Mocroft, A

AU - EuroSIDA in EuroCoord

AU - van Lunzen, Jan

N1 - © 2013 British HIV Association.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - OBJECTIVES: All HIV/hepatitis C virus (HCV)-coinfected patients with chronic HCV infection and ≥ F2 fibrosis should be considered for HCV therapy. This study aimed to determine the rate of HCV treatment uptake among coinfected patients in Europe.METHODS: EuroSIDA patients with viraemic HCV infection were included in the study. Poisson regression was used to identify temporal changes and regional differences in HCV treatment uptake.RESULTS: A total of 1984 patients were included in the study, with a median follow-up time of 168 months [interquartile range (IQR) 121-204 months]. To date, 501 (25.3%) HIV/HCV-coinfected patients have received HCV therapy. Treatment incidence rose from 0.33 [95% confidence interval (CI) 0.16-0.50] per 100 person-years of follow-up (PYFU) in 1998 to 5.93 (95% CI 4.49-7.38) in 2007, falling to 3.78 (95% CI 2.50-5.07) in 2009. After adjustment, CD4 cell count > 350 cells/μL [incidence rate ratio (IRR) 1.33 (95% CI 1.06-1.67) vs. CD4 count 200-350 cells/μL] and ≥F2 liver fibrosis [IRR 1.60 (95% CI 1.14-2.25; P = 0.0065) vs. < F2 fibrosis] were predictors of anti-HCV treatment initiation. However, 22% of patients who remain untreated for HCV, with fibrosis data available, had ≥F2 fibrosis and should have been considered for treatment, while only 36% of treated patients had ≥F2 fibrosis.CONCLUSIONS: Although treatment incidence for HCV has increased, there remain a large proportion of patients indicated for treatment who have yet to be treated.

AB - OBJECTIVES: All HIV/hepatitis C virus (HCV)-coinfected patients with chronic HCV infection and ≥ F2 fibrosis should be considered for HCV therapy. This study aimed to determine the rate of HCV treatment uptake among coinfected patients in Europe.METHODS: EuroSIDA patients with viraemic HCV infection were included in the study. Poisson regression was used to identify temporal changes and regional differences in HCV treatment uptake.RESULTS: A total of 1984 patients were included in the study, with a median follow-up time of 168 months [interquartile range (IQR) 121-204 months]. To date, 501 (25.3%) HIV/HCV-coinfected patients have received HCV therapy. Treatment incidence rose from 0.33 [95% confidence interval (CI) 0.16-0.50] per 100 person-years of follow-up (PYFU) in 1998 to 5.93 (95% CI 4.49-7.38) in 2007, falling to 3.78 (95% CI 2.50-5.07) in 2009. After adjustment, CD4 cell count > 350 cells/μL [incidence rate ratio (IRR) 1.33 (95% CI 1.06-1.67) vs. CD4 count 200-350 cells/μL] and ≥F2 liver fibrosis [IRR 1.60 (95% CI 1.14-2.25; P = 0.0065) vs. < F2 fibrosis] were predictors of anti-HCV treatment initiation. However, 22% of patients who remain untreated for HCV, with fibrosis data available, had ≥F2 fibrosis and should have been considered for treatment, while only 36% of treated patients had ≥F2 fibrosis.CONCLUSIONS: Although treatment incidence for HCV has increased, there remain a large proportion of patients indicated for treatment who have yet to be treated.

KW - Adult

KW - Antiviral Agents

KW - CD4 Lymphocyte Count

KW - Cohort Studies

KW - Coinfection

KW - Drug Therapy, Combination

KW - Europe

KW - Female

KW - HIV Infections

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Liver Cirrhosis

KW - Male

KW - Middle Aged

KW - Patient Acceptance of Health Care

KW - Poisson Distribution

KW - Prospective Studies

KW - Ribavirin

U2 - 10.1111/hiv.12068

DO - 10.1111/hiv.12068

M3 - SCORING: Journal article

C2 - 23869664

VL - 14

SP - 614

EP - 623

JO - HIV MED

JF - HIV MED

SN - 1464-2662

IS - 10

ER -